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Abstract
Spondyloarthropathies are a group of disorders having some common fea-
tures. They are characterised by inflammation of the attachment of tendons 
known as enthesitis. They are common in males. There is a familial occurrence. 
There is an association with HLA-B 27. Rheumatoid factor will be negative. Axial 
skeleton involvement in the form of sacroiliitis or spondylitis is common. The 
common conditions include ankylosing spondylitis, Reiter’s disease, psoriatic 
arthritis, enteropathic arthritis and reactive arthritis. In this chapter we are 
going to describe the clinical features, evaluation and management of common 
spondyloarthropathies.
Keywords: spondyloarthropathies, ankylosing spondylitis, enteropathic arthritis, 
reactive arthritis, psoriatic arthritis
1. Introduction
Spondyloarthropathies are a group of disorders having common clinical 
features and are characterised by inflammation of the attachment of tendons 
known as enthesitis. They are common in males and show familial inheritance 
patterns. The HLA-B 27 allele is frequently associated with these disorders. A 
rheumatoid factor assay will be negative (seronegative spondyloarthropathy). 
Axial skeleton involvement in the form of sacroiliitis or spondylitis is common. 
The common conditions include ankylosing spondylitis, Reiter’s disease, psori-
atic arthritis, enteropathic arthritis and reactive arthritis [1, 2]. In this chapter 
we describe the classification, clinical features, evaluation and management of 
common spondyloarthropathies.
2. Classification
A broad clinical classification of spondyloarthropathies into those having a 
primary axial involvement, those with a predominant peripheral involvement, and 
those with a hybrid form of affliction, although eases clinical practise, is difficult 
to reproduce with uniformity. The current favourite diagnostic criteria, The modi-
fied New York criteria for AS is heavily dependent on axial spine affliction and 
recognises advanced structural damage thus reducing the importance of early extra 
spinal manifestations, serological evidence and genetic predisposition. There is no 
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emphasis on detection of early radiological manifestations by more informative 
imaging techniques like magnetic resonance scanning. Inflammatory back pain, the 
leading clinical symptom of spinal and sacroiliac affliction has been defined by many 
criteria although its diagnostic significance has not been completely understood 
and the sensitivity and specificity offered by it is low. It is efficient in diagnosing 
definite cases although a classification of disease based on it leaves much confusion. 
The Assessment of SpondyloArthritis International Society axial spondyloarthritis 
criteria (axSpA) allows for earlier detection of disease thus facilitating earlier disease 
modification and is more comparable across studies. The focus of treatment in 
spondyloarthropathies has shifted on to earlier diagnosis and treatment. Magnetic 
resonance imaging and specific serological tests such as the HLA-B 27 form an 
essential component of this strategy. In 2011 the ASAS described the peripheral 
spondyloarthritis criteria specially aimed at the cohort of patients with no or non-
specific back pain but with predominant peripheral manifestations [3–5].
3. Ankylosing spondylitis (AS)
This is the prototype disease among spondyloarthropathies. It is also known as 
Marie-Strumpell disease or Von Bechterew disease. The exact aetiology is unknown. 
It mainly involves spine and major joints like hip and knee. Sacroiliitis is one of 
the cardinal features of this disease. It usually affects males in the second or third 
decade of life. The male to female ratio is 3:1.
There is a striking correlation between AS and HLA-B27 antigen. The disease 
occurs more frequently in Caucasians where HLA-B27 prevalence is higher as com-
pared to African Americans or Africans of unmixed ancestry. About 1–2% of adults 
inheriting HLA-B2 antigen have ankylosing spondylitis. In families of patients with 
AS there is 10–20% prevalence of this antigen. There is no direct causative relation-
ship between HLA-B27 antigen and AS. There is a strong association between AS and 
inflammatory bowel diseases like ulcerative colitis and Crohn’s disease. Both genetic 
and environmental factors play a role in the pathogenesis of ankylosing spondylitis [6].
3.1 Pathology and pathogenesis
Sacroiliac inflammation is the earliest feature of AS with inflammatory granula-
tion tissue eroding the sacroiliac joint. The inner and thinner iliac cartilage is eroded 
before the thicker outer sacral sided cartilage. This leads to fibrocartilage tissue 
replacing the joint space followed by bony ankylosis of sacroiliac joints. There is 
diffuse osteoporosis of the vertebrae. The inflammation stars at the junction of the 
intervertebral disc and body. Inflammation and erosion proceeds at the bone disc 
interface and new bone formation occurs from the edges of the annulus fibrosus 
known as syndesmophytes. They grow vertically upwards and bridge the adjacent 
vertebrae producing bamboo spine appearance in radiograph. Early on, inflam-
mation at the bone disc interface produces corner shining sign and later erosion 
produces squaring of vertebrae. Arthritis of apophyseal joint leads to erosion and 
later ankylosis of the same. Inflammation and erosion at the sites of attachment of 
ligaments and tendons are common. Enthesitis followed by calcification is common 
in the axial skeleton. Unlike in rheumatoid arthritis destruction of central cartilage 
due to granulation and pannus in peripheral joints can occur in AS. There can be 
synovitis in peripheral joints.
Extra articular involvement like recurrent uveitis, aortic regurgitation, inflam-
matory lesions of colon and ileocecal valve and IgA nephropathy are seen in some 
cases [6, 7].
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The exact mechanism of pathogenesis is unknown. It is thought that the 
destruction is mediated through immunological mechanisms. The elevated levels of 
inflammatory reactants, Ig A levels in serum and histology suggest inflammation 
in AS. The exact environmental trigger is not yet identified although elevated levels 
of antibodies to Klebsiella pneumoniae are seen in AS patients. There is no causative 
association between ankylosing spondylitis and HLA-B27 [8, 9].
3.2 Clinical features
The disease is common in males and in the second and third decade of life. The com-
mon presentation in majority of patients is dull aching low back pain which is progressive. 
There is morning stiffness lasting for few hours and decreased by activity. Pain increasing 
with rest and improving with exercise is a characteristic feature. Nocturnal exacerbation 
of pain awakening the patients making them move around is also common. Exacerbations 
and remissions of symptoms are also common. The enthesitis produces pain in the 
costochondral junction, greater tuberosity, tibial tuberosity and spinous processes. In 
some patients the presenting symptom is intractable plantar fasciitis. Neck pain and 
involvement of cervical spine is late. Sometimes, patients present with features of arthritis 
in hip or shoulder. Peripheral asymmetrical joint arthritis is rarely seen. Constitutional 
symptoms like fever, anorexia, weight loss and night sweats can occur rarely.
The common extra articular involvement is ophthalmic. It is usually uni-ocular 
uveitis. Occasionally it precedes low back symptoms. Red eye, pain, photophobia 
and increased lacrimation are common. Aortic regurgitation is seen in some 
patients and can lead to congestive cardiac failure. AS may be associated with 
inflammatory bowel disease in many patients [8–10].
Tenderness can be elicited over sacroiliac joints, spinous process and areas of 
enthesitis. The most common feature is loss of mobility of the spine. It is partially 
due to bony ankylosis and partially due to paraspinal muscle spasms. Forward 
flexion, lateral rotation and extension of spine are limited. There is loss of lumbar 
lordosis, increased thoracic kyphosis, flexion deformity of cervical spine flexion 
deformity of knee. Later this leads to stooping forward posture. This can be demon-
strated by occipital wall test. The decreased excursion of lumbar spine movement 
can be demonstrated by using modified Schober’s test. Costovertebral joint involve-
ment can be detected by decreased chest expansion. Sacroiliitis is characterised by 
local tenderness. Sacroiliac stress test like FABER test, pump handle test can be done 
though not specific. There can be features of arthritis with ankylosis of hip joints and 
shoulder. Peripheral joints involvement needs to be evaluated in all cases [8–10].
Earlier onset of disease signals a poor prognosis. They will have severe arthritis of 
hip. Women have lesser involvement of axial skeleton, mostly isolated involvement of 
cervical spine and peripheral joints. Due to spinal osteoporosis there can be fractures 
of spine even with minor trauma. It is common in cervical spine leading to quadriple-
gia. This is one of the cause of death in AS. There are reports of pulmonary fibrosis, 
cardiac conduction defects and chronic prostatitis in long standing AS [10, 11].
Restrictive lung disease due to bilateral pulmonary fibrosis can occur. 
Superadded aspergillosis may mimic tuberculosis. Insertional tendinitis of cos-
tosternal and costovertebral muscles leads to pleuritis. Chest expansion is compro-
mised due to fusion of costovertebral joints. There is a threefold increase in risk of 
death due to respiratory causes in AS patients than in normal people [10, 11].
3.3 Investigations
There is no diagnostic investigation for AS. In the active stage of disease ESR and 
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be elevated. Occasionally normocytic normochromic anaemia is associated. There 
is an elevated IgA level in most cases. HLA-B27 will be elevated. Synovial fluid 
examination is usually inconclusive. Rheumatoid factor and antinuclear antibodies 
will be uniformly absent. Pulmonary function tests show reduced vital capacity and 
increased residual capacity.
Radiograph of the sacroiliac joints shows bilateral involvement. The initial stage 
is characterised by blurring of the subchondral bone followed by erosion and scle-
rosis. Progressive erosion produces pseudo widening of the joints. Later progressive 
bony ankylosis of bilateral sacroiliac joints is seen. These changes are detected by 
computerised tomography and MRI at an earlier stage than plain radiograph [12].
In the spine there is diffuse osteoporosis. The initial stages show reactive osteitis 
at the corners of vertebrae producing corner shining sign on lateral view. Later ero-
sion of the corner area produces squaring of the vertebrae. Syndesmophytes grow-
ing vertically from the margins of intervertebral disc bridge the adjacent vertebrae 
and lead to the typical bamboo spine appearance. Lumbar lordosis is lost and dorsal 
kyphosis is exaggerated.
Articular erosion in the hip leads to features of arthritis and sometimes protrusio 
acetabuli, later progressing to bony ankylosis. Even though majority of patients 
have some functional impairment they can lead a fairly normal life [12, 13].
3.4 Diagnosis and differential diagnosis
The most common presenting symptom of AS is inflammatory back pain char-
acterised by pain low back of more than 3 months duration, pain aggregated with 
inactivity and relieved with activity, presence of morning stiffness and insidious 
onset in younger patients below the age of 40. But it will be difficult to diagnose AS 
early before the development of sacroiliitis of spinal deformities. It has been shown 
that people positive for HLA-B27 developing sacroiliitis at a later date. Because of 
these difficulties a criteria was developed for the diagnosis of AS. The modified 
New York criteria consist of (1) history of inflammatory back pain, (2) reduced 
range of movement of lumbar spine both in frontal and sagittal planes, (3) reduced 
chest expansion, (4) radiographic evidence of sacroiliitis. The criteria suggest that 
the presence of radiographic sacroiliitis with any other criteria can make a diagnosis 
of ankylosing spondylitis.
There are a few conditions which can mimic AS. Diffuse idiopathic skeletal 
hyperostosis (DISH) is one differential diagnosis but this seen in elderly usually 
calcification is unilateral on the right side, intervertebral spaces are maintained. 
Radiogram shows ossified anterior spinal ligament as flowing wax. Fluorosis is 
another disease but this is usually endemic to certain areas and calcification of sac-
roiliac and sacrotuberous and other ligamentous calcifications are characteristics. 
Ochronosis and hemochromatosis can produce intervertebral disc calcification but 
can be differentiated from AS by other features [14, 15].
3.5 Treatment
There is no medical cure for ankylosing spondylitis. Treatment aims to maintain 
a functional posture and preserve joint mobility. Exercise can improve and preserve 
mobility. Swimming and yoga are also helpful. In the active stages NSAIDs espe-
cially indomethacin is very useful. Intra-lesional and intra-articular glucocorticoid 
injections are useful for symptomatic relief of enthesitis or peripheral joint arthri-
tis. Guided glucocorticoid injections are also useful for the relief of sacroiliitis. 
Sulphasalazine is useful for the long term control of peripheral joint arthritis. 
Peripheral joint symptoms can also be controlled using methotrexate.
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The most common surgical treatment is for hip arthritis. Total hip replacements 
can improve the pain and joint stiffness. Usually hip involvement produces flexion 
deformity which leads to flexion of knee. Total hip replacement can improve the gait 
and posture of patients [14, 15].
A fixed kyphotic deformity at the cervicothoracic junction can lead to chin on 
chest deformity. This is a rare and disabling condition. A posterior cervicothoracic 
extension osteotomy can be done for this deformity. It helps in restoration of head 
and neck posture, relieves pain and improves function. Severe kyphotic deformity 
of dorsal spine can produce pain and inability to stand straight. This can be man-
aged by an extension osteotomy like Watson Jones osteotomy [16–18].
Mydriatics and local glucocorticoid administration are indicated for iritis. Aortic 
valve replacement may be needed for aortic valve insufficiency and pacemaker for 
conduction defects [18].
4. Other spondyloarthropathies
4.1 Reactive arthritis or Reiter’s syndrome
It is an acute nonpurulent arthritis occurring following an episode of enteric 
or urogenital infection in HLA-B27 positive people. Formerly the classical triad of 
urethritis, arthritis and conjunctivitis was known as Reiter’s syndrome. Although 
Reiter’s syndrome is one among the reactive arthritis this term is not used currently. 
All spondyloarthropathies occurring following urogenital or enteric infections 
are termed reactive arthritis even if all classical features of Reiter’s syndrome are 
not present. Shigella, Salmonella, Yersinia and Campylobacter are the common 
organisms that cause enteric infection associated with reactive arthritis. Chlamydia 
trachomatis is the commonest urogenital infection leading to reactive arthritis. 
When reactive arthritis occur following a sexually transmitted urogenital infec-
tion it is termed as Sexually transmitted associated reactive arthritis (SARS), and 
when occur following gut related infections called Gut associated reactive arthritis 
(GARS). There is no gender predilection and occurrence is equal in males and 
females. Although it can occur at any age, commonly affected are individuals of 
the age group of 20 to 40 years. Similar to ankylosing spondylitis, there is a close 
association between HLA-B27 and reactive arthritis [19].
Pathology is similar to other inflammatory arthritis. Enthesitis is also common. 
Keratoderma blenorrhagica is a skin condition associated with reactive arthritis 
especially with urogenital infections. The exact triggering mechanism for the 
pathogenesis of reactive arthritis is unknown. There are reports of acute nonpuru-
lent arthritis associated with bacterial, viral and even parasitic infections. Like in 
ankylosing spondylitis it is mediated through immunological mechanisms. There is 
persistence of organism in the inflamed synovium for prolonged duration although 
not demonstrated in blood. The role of HLA-B27 also remains unclear.
4.2 Clinical features
The clinical features can range from mild mono articular involvement to asym-
metrical poly articular arthritis. Most patients will give a history of antecedent 
infection either in the GI tract or urogenital region. Sometimes, there is a history 
of sexual promiscuity. In males, urethritis or prostatitis and in females cervicitis 
or salpingitis may be present though asymptomatic. Unlike ankylosing spondyli-
tis, constitutional symptoms like fatigue, malaise, fever are common in reactive 
arthritis. The arthritis typically involves the lower limb joints. Knee, ankle, subtalar, 
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metatarsophalangeal joints and inter-phalangeal joints are commonly involved. 
There is asymmetrical involvement and usually migrates from one joint to another 
over a period. Wrist and fingers can also be involved. Painfull joints with tense 
effusion are common especially in large joints like knee. Dactylitis with sausage 
digits can occur in single or multiple fingers. Enthesitis producing symptoms of 
insertional tendo achilles tendinitis and plantar fasciitis can be seen. Low back pain 
due to sacroiliitis, enthesitis is also seen [20].
Extra articular lesions like conjunctivitis and severe uveitis can cause blindness 
in certain patients with reactive arthritis. Vesicular and hyperkeratotic lesions seen 
in hand and foot are called Keratoderma blenorrhagica. Circinate balanitis of glans 
penis is also described. Like in ankylosing spondylitis aortic regurgitation, cardiac 
conduction defects and pulmonary involvement can rarely occur [21].
4.3 Investigations
In the acute phase there will be elevated ESR and CRP. Synovial fluid analysis is 
inconclusive. Occasionally there is a marked elevation of antibodies to salmonella, 
chlamydia and yersinia indicating recent infections with these organisms.
Radiograph will be normal in early cases. Later on, peri-articular osteoporosis 
develops in chronic cases followed by juxtaarticular erosions and loss of joint space. 
New bone formation due to periostitis can occur. Spur formation at the attachments 
of tendons are also seen. Sacroiliitis and spondylitis occur very late and are uncom-
mon. Sacroiliitis is unilateral and asymmetrical. Unlike in ankylosing spondylitis 
the spondylitis may not show an ascending pattern and it can involve any level. 
The syndesmophytes may be coarse and nonmarginal arising from the middle of 
vertebrae. Spinal fusion is very rare [21, 22].
4.4 Diagnosis and differential diagnosis
Diagnosis is based on clinical examination as there is no confirmatory laboratory 
test available. A careful history of recent infection in the gut and urogenital tract is 
to be elicited. Careful examination of genitalia, eye, skin, nail and mucous mem-
branes must be done. In doubtful cases HLA-B27 testing can be done [23].
The most common differential diagnosis is gonococcal arthritis. But it involves 
both lower and upper limbs equally. Low back pain is not seen in gonococcal 
arthritis. Characteristic vesicular skin lesions are common. Culturing gonococci 
from blood, skin lesion or synovium establishes the diagnosis. Psoriatic arthritis is 
another differential diagnosis [24].
Undifferentiated spondyloarthropathies can present like reactive arthritis. They 
may present with isolated arthritis involving knee, ankle or dactylitis or enthesitis 
like plantar fasciitis and insertional tendo achilles tendinitis. They may not meet the 
diagnostic characteristic of other classical spondyloarthropathies. Approximately half 
of patients with undifferentiated spondyloarthropathies are HLA-B27 positive [23, 24].
4.5 Treatment
Most patients with reactive arthritis respond well to NSAIDS for symptomatic 
relief. Indomethacin 75–150 mg in divided doses is the initial treatment of choice. 
Sulphasalazine up to 3 g/day may be helpful especially patients not responding to 
NSAIDS. Immunosuppressive agents such as azathioprine 1–2 mg/kg per day and 
methotrexate 7.5–15 mg per week are useful. Tendinitis and enthesitis can be treated 
with intra lesional glucocorticoid injections. Uveitis may require aggressive treat-
ment with glucocorticoid to prevent blindness [21, 23].
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5. Psoriatic arthritis
Since the association between HLA-B27 and psoriatic spondylitis (60%) is less 
when compared to AS (94%) it is included in spondyloarthropathies. About 2% of 
individuals having psoriasis develop arthritis. Peripheral arthritis is common than 
axial disease. In majority of patients skin lesions predate arthritis. But in one fourth 
of cases the skin lesions appear simultaneously or arthritis predate skin lesions. In 
such cases a there may be a family history of psoriasis. Nail changes like ridging, 
pitting and onycholysis are common in psoriatic arthritis. Though psoriatic distal 
inter-phalangeal joint arthritis is common in males incidence is similar in both 
sexes. There are many forms of psoriatic arthritis [25].
1. Oligoarticular disease (70%): it is the most common type of psoriatic arthritis. 
Asymmetrical arthritis involving the lower limb joints is common. It can 
involve small joints of fingers. Both distal and proximal inter-phalangeal joints 
are involved- sausage fingers. Lack of distal inter-phalangeal joint involvement 
helps to differentiate it from rheumatoid arthritis. Nail changes are frequent in 
fingers having distal inter-phalangeal involvement.
2. Symmetrical polyarthritis (15%): it may be indistinguishable from rheumatoid 
arthritis. But presence of rheumatoid nodules and distal inter-phalangeal 
joint involvement and positive rheumatoid factor helps to distinguish it from 
rheumatoid arthritis.
3. Arthritis mutilans (5–10%): it is a severe destructive asymmetrical arthritis. It 
is usually seen in severe form of psoriasis. It is associated with sacroiliitis and 
spondylitis.
4. Psoriatic spondylitis (25%): it is strongly associated with HLA-B27 (60%). 
Majority of cases are asymptomatic. Asymmetrical sacroiliitis is common. 
Spondylitis without sacroiliitis producing florid syndesmophyte formation is 
common in psoriasis.
Features like distal inter-phalangeal joint involvement, absent peri articular 
osteoporosis, periostitis, ankylosis, pencil in cup deformities of DIP joints and axial 
skeleton involvement in radiograph help to differentiate it from rheumatoid arthri-
tis. Sometimes, concomitant gouty arthritis can be seen even in premenopausal 
women due to high skin cell turnover [26, 27].
5.1 Treatment
Majority of cases are oligoarticular and mild and have good prognosis. NSAIDS 
are the mainstay of symptomatic treatment. Intra-articular glucocorticoid injec-
tions are helpful in oligoarticular disease. Methotrexate and azathioprine are useful 
for long term control of both skin and arthritic lesions. Antimalarial and systemic 
steroids must be avoided for the fear of exacerbation of skin lesions [28].
6. Enteropathic arthritis
Seronegative spondyloarthropathies can occur in association with inflammatory 
bowel disorders (IBD). They are twice commonly associated with Crohn’s disease 
than ulcerative colitis. Two forms of peripheral arthritis are described.
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Type 1: it is strongly associated with extra intestinal manifestations of 
IBD. It is usually pauciarticular and is seen during relapses of IBD. It is acute and 
self-limiting.
Type 2: more than five joints are involved. It runs a chronic course lasting for 
years independent of the IBD. Uveitis can occur but other extra intestinal manifes-
tations are rare.
Extra articular manifestations like erythema nodosum, pyoderma gangrenosum, 
aphthous stomatitis can occur. Exact pathogenesis of enteropathic arthritis is not 
known. Increased gut permeability leading to entry of bacilli from gut into general 
circulation and immune mediated mechanism is one proposed theory [29, 30].
6.1 Treatment
There will be intolerance to NSAIDS due to gastrointestinal involvement. Hence 
simple analgesics are used. Intra-articular glucocorticoid injections are useful. 
Sulfasalazine is useful for the control of both arthritis and gut disease. Systemic 
corticosteroids, methotrexate and azathioprine are also used [30, 31].
6.2 Biological DMARDs in spondyloarthropathies
Treatment with biological agents is used in patients who fail to respond to 
NSAIDs. It should be started at an early stage to prevent progression. Tumour necro-
sis factor alpha inhibitors are the commonest drugs used. They prevent cartilage 
damage in peripheral joints than in axial joints. These drugs reduce the radiographic 
progression of disease in AS when administered early. Highest response to these 
drugs occurred in psoriatic arthritis patients with elevated CRP levels. Due to fear 
of reactivation it is always better to screen for the presence of latent tuberculosis or 
hepatic viral diseases [30]. In addition to biological agents the ASAS recommends a 
single local corticosteroid injection in cases of peripheral spondyloarthritis.
7. Tumour necrosis factor alpha inhibitors
Etanercept, infliximab, adalimumab, golimumab, certolizumab are the common 
TNF alpha inhibitors used. Infliximab is used intravenously and the others are adminis-
tered subcutaneously. They are effective for spondyloarthropathies and psoriatic arthritis 
which are not controlled by NSAIDS and traditional DMARDS. Certolizumab, a recent 
drug is effective in reducing the symptoms and axial involvement in AS. Infliximab, 
adalimumab, golimumab are used in IBD to treat both bowel and joint diseases. 
Etanercept is useful in controlling axial skeleton involvement but its effect on enteric 
disease is limited. Infliximab and adalimumab used in AS have shown to decrease the rate 
of recurrences. Golimumab is found to be effective in refractory uveitis associated with 
spondyloarthropathies. TNF-alpha inhibitors like infliximab, adalimumab, golimumab, 
and etanercept are very efficient in treating the skin and nail lesions in psoriasis though 
exacerbations of lesions can occur rarely with TNF alpha inhibitors. TNF alpha inhibi-
tors decrease cardiovascular manifestations. In AS, the overall treatment with biological 
DMARDS shows only partial remission or low disease activity [32–34].
Interleukin-6 receptor inhibitors like Tocilizumab and Sarilumab are found to be 
not effective in the treatment of spondyloarthropathies by various trials. A shot-
term study involving 30 patients with AS treated using Secukinumab showed its 
clinical efficacy but need to be confirmed by long term RCTS. Ustekinumab, a fully 
human monoclonal antibody against a common subunit of lL12 and IL 23, is well 
tolerated and found to be effective in AS and psoriatic arthritis [35].
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8. Current consensus and the way forward
The 2016 update on Assessment of SpondyloArthritis international Society 
(ASAS)-European league against rheumatism (EULAR) recommendations provide 
guidance on the management of patients with axial spondyloarthritis. A total of five 
broad principles of management and treatment recommendations have been put 
forward. They are precise guidelines to treat patients with axial spondyloarthropa-
thies broadly incorporating therapeutic and diagnostic concerns [36].
9. Conclusion
Spondyloarthropathies are a group of conditions having some common overlap-
ping clinical features. They are common in HLA-B27 antigen positive individuals. 
There is no conclusive investigation for these conditions hence differentiation is dif-
ficult at least in the early stages. For most of the cases only symptomatic treatments 
are available. Further research is needed for early detection and accurate treatment 
of these conditions.
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